The cytochromes P‐450 are not involved in the modulation of the N‐methyl‐D‐aspartate response by sigma ligands in the rat CA3 dorsal hippocampus
- 1 January 1993
- Vol. 13 (1) , 30-38
- https://doi.org/10.1002/syn.890130105
Abstract
Recent in vitro radioligand binding studies have shown that several cytochrome P‐450 inhibitors can displace [3H] sigma ligands, suggesting that these ligands might bind to the cytochrome P‐450 superfamily of enzymes. Using an in vivo electrophysiological model of extracellular recordings performed in the CA3 region of the rat dorsal hippocampus, we have previously shown that intravenous administration of low doses of several sigma ligands, such as 1, 3‐di(2‐tolyl) guanidine (DTG), JO‐1784, and (+)pentazocine potentiate the neuronal response induced by microiontophoretic applications of N‐methyl‐D‐aspartate (NMDA) without affecting those induced by quisqualate and kainate, suggesting that they act as sigma agonists. Conversely, the sigma ligands haloperidol, (+)3‐PPP, and BMY‐14802, which have no effect by themselves on the NMDA response, prevent and suppress the potentiating effect of sigma agonists on the NMDA response, suggesting that they act as sigma antagonists. The present studies were undertaken to determine if cytochromes P‐450 could be involved in the modulation of the NMDA response by sigma ligands. For this purpose, two cytochrome P‐450 inhibitors, proadifen (SKF‐525A) and piperonyl butoxide (PB), have been tested in our model. Unlike sigma agonists, at low doses, neither SKF‐525A nor PB affected the NMDA response of CA3 dorsal hippocampus pyramidal neurons. Unlike sigma antagonists, neither of these drugs reversed or prevented the DTG‐induced potentiation of the NMDA response. In addition, following high doses of SKF‐525A or PB, sufficient to induce a complete inactivation of cytochromes P‐450, DTG still potentiated the NMDA response. The present data suggest that cytochrome P‐450 inhibitors do not modulate the NMDA response like sigma agonists or antagonists do in this brain region. Furthermore, they rule out the involvement of cytochromes P‐450 in the modulation of the NMDA response by sigma ligands.Keywords
This publication has 22 references indexed in Scilit:
- SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorpan and σ ligands to guinea pig brain.Life Sciences, 1991
- Cytochrome P450 enzymes: ubiquitous "receptors" for drugsCanadian Journal of Physiology and Pharmacology, 1991
- Is the Sigma Opiate Receptor a Proadifen‐Sensitive Subform of Cytochrome P‐450?Basic & Clinical Pharmacology & Toxicology, 1990
- JO 1784, a potent and selective ligand for rat and mouse brain σ-sitesJournal of Pharmacy and Pharmacology, 1990
- Regional Distribution of Cytochrome P‐450 in the Rat Brain: Spectral Quantitation and Contribution of P‐450b,e and P‐450c,dJournal of Neurochemistry, 1988
- Potential antipsychotic BMY 14802 selectively binds to sigma sitesDrug Development Research, 1987
- Inhibitors of Cytochrome P-450s and Their Mechanism of ActionDrug Metabolism Reviews, 1981
- Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brainNeuropharmacology, 1977
- Antischizophrenic Drugs: Chronic Treatment Elevates Dopamine Receptor Binding in BrainScience, 1977
- Structure-activity relations for methylenedioxyphenyl and related compounds on hepatic microsomal enzyme function, as measured by prolongation of hexobarbital narcosis and zoxazolamine paralysis in miceToxicology and Applied Pharmacology, 1970